Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Better Stock Today Challenge: Isis Pharmaceuticals vs. Energy Transfer Partners

In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner.

Today it's the round of 16, and Isis Pharmaceuticals  (NASDAQ: ISIS  ) takes on Energy Transfer Partners  (NYSE: ETP  ) in our search for the better stock.

David Williamson, Motley Fool health care analyst, thinks Isis should advance to the next round because of one big reason -- its amazing drug pipeline. Wall Street heralds it as the best in biotech and puts Isis in play as a takeover target. A virtual who's who of big pharma has struck partnership deals. Isis already has orphan drug Kynamro on the market, and has seen recent success from a mid-stage study for an anti-clotting drug. A recent sell-off has given investors a chance to get this deep pipeline at a discounted price.

Joel South, energy analyst at The Motley Fool, thinks Energy Transfer Partners is a great investment for dividend lovers. The Master Limited Partnership currently distributes a very respectable 6.6% yield, but with strong segment diversification, a proven track record of executing on project backlogs and a built out pipeline infrastructure ready to service U.S. LNG exports, distributable cash flows should continue to pick up for unitholders.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Vote here to determine the winner of this match and sound off in the comments. Check back to to see who advances in the tournament.

Read/Post Comments (2) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 21, 2014, at 12:10 AM, tbash789 wrote:

    ISIS has six top flight drugs that ready for prime time in the very near future. As is their goal to have all of the drugs to be first in-class and best in-class they are going to come close if they don't make that goal entirely.

    Their glucagon receptor blocker recently came out with unbelievable data for only a 13 wk trial. At the 200 mg dosing they lowered the average patients HgbA1c by greater than 2.5%(unheard of). The 100mg dosing lowered the average patients HgbA1c by greater than 1.25% both after the adjustment for placebo. This drug does not cause the problems with nausea and vomiting that the GLP-1 agonists can. And it doesn't cause the negative effects on blood pressure, and severe fatty infiltration of the liver like the oral GCGR inhibitors do. Almost all big pharmas have failed with their attempt at an oral med for this target. LLY is the only one left.

    Their TTRR-amyloidosis drug that they have partnered with GSK looks to be a huge potential winner. ISIS has at least a 24 month head start on their nearest competitor. It lowers the target on average by 75%, is given easily in the home by the patient once a week. This will be an orphan drug for this disease.

    Their ApoCIII drug that has gotten all the attention lately lowers ApoCIII by over 70%. ApoC III is a CV risk factor by itself. The drug lowers triglycerides by over 65% on average, and raises HDL by 55% on average, and lowers your HgbA1c by 1.2% on average in diabetics. This is where I disagree with Dr. Topol. Most patients on statin drugs were not taking them life-long either and they still see a benefit from their use. Moreover, some lipid experts think that this target, ApoC III, is the master modulator of lipids. This drug instead of making you more prone to DM Type2 like a statin drug does, this actually lowers your risk of DM Type2, and if you already have the disease we know at least so far from studies as noted above it lowers your HgbA1c in diabetic patients treated with the drug by 1.2% after correction from placebo. It also has the potential to lower CV by maybe 40% compared to statins 25 to 30%.

    Their STAT-3 CA drug has huge potential in multiple CA's including Large B-cell lymphoma, liver cancer, and one type of brain CA. The slides that ISIS has that shows the regression in three women who failed over six different treatments and were about to go on Hospice is truly remarkable. It is also showing some potential in immunology and allergies.

    The SMN atrophy drug looks to be the leader in the orphan drug space for the most prevalent genetic illness that kills infants. Great strides are being made in the fighting of this drug with ISIS medication leading the way. Go to the SMN foundation to see for yourself.

    The Factor XI inhibitor could be the biggest drug of all. It could have many potential uses. In their studies ISIS drug beat the standard of care, that being Lovenox with a seven fold decrease in post knee replacement deep vein thrombosis. And at the same time there were NO bleeds. It could become the standard of care for patients with chronic kidney disease and atrial fibrillation.

    The list goes on and on, these are but a few of the potential block-busters that could come out of ISIS. The other company has a nice dividend, but with ISIS one year's appreciation.....especially now, one could equal a decade of interest payments and price appreciation with the other company by buying and holding ISIS for one year. t

  • Report this Comment On June 23, 2014, at 10:33 AM, km00nster wrote:

    Wow very well said tbash!! Thanks for all that information.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3001917, ~/Articles/ArticleHandler.aspx, 9/4/2015 1:00:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated Moments ago Sponsored by:
DOW 16,078.45 -296.31 -1.81%
S&P 500 1,919.83 -31.30 -1.60%
NASD 4,676.64 -56.86 -1.20%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 12:44 PM
ETP $48.05 Down -0.40 -0.82%
Energy Transfer Pa… CAPS Rating: *****
ISIS $51.74 Up +0.17 +0.33%
Isis Pharmaceutica… CAPS Rating: *****